Abstract
C-reactive protein (CRP) as an indicator of cardiovascular disease (CVD) has shown limited sensitivity. We demonstrate that two isoforms of CRP (pentameric, pCRP and monomeric, mCRP) present in soluble form or on microparticles (MPs) have different biological effects and are not all measured by clinical CRP assays. The high-sensitivity CRP assay (hsCRP) did not measure pCRP or mCRP on MPs, whereas flow cytometry did. MPs derived from endothelial cells, particularly those bearing mCRP, were elevated in peripheral artery disease (PAD) patients compared to controls. The numbers of mCRP+ endothelial MPs did not correlate with hsCRP measurements of soluble pCRP, indicating their independent modulation. In controls, statins lowered mCRP+ endothelial MPs. In a model of vascular inflammation, mCRP induced endothelial shedding of MPs and was proinflammatory, while pCRP was anti-inflammatory. mCRP on endothelial MPs may be both an unmeasured indicator of, and an amplifier of, vascular disease, and its detection might improve risk sensitivity.
Similar content being viewed by others
Abbreviations
- CRP:
-
C-reactive protein
- hsCRP:
-
high-sensitivity CRP assay
- mCRP:
-
monomeric CRP
- MNL:
-
mononuclear leukocyte
- MP:
-
microparticle
- PAD:
-
peripheral artery disease
- pCRP:
-
pentameric CRP
- TEM:
-
transendothelial migration
References
Ansar, W., & Ghosh, S. (2013). C-reactive protein and the biology of disease. Immunologic Research, 56(1), 131–142. doi:10.1007/s12026-013-8384-0.
Eisenhardt, S. U., Habersberger, J., Murphy, A., Chen, Y. C., Woollard, K. J., Bassler, N., et al. (2009). Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circulation Research, 105(2), 128–137. doi:10.1161/CIRCRESAHA.108.190611.
Habersberger, J., Strang, F., Scheichl, A., Htun, N., Bassler, N., Merivirta, R. M., et al. (2012). Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. Cardiovascular Research, 96(1), 64–72. doi:10.1093/cvr/cvs237.
Paul, A., Ko, K. W., Li, L., Yechoor, V., McCrory, M. A., Szalai, A. J., et al. (2004). C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation, 109(5), 647–655. doi:10.1161/01.CIR.0000114526.50618.24.
Hirschfield, G. M., Gallimore, J. R., Kahan, M. C., Hutchinson, W. L., Sabin, C. A., Benson, G. M., et al. (2005). Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 102(23), 8309–8314. doi:10.1073/pnas.0503202102.
Kovacs, A., Tornvall, P., Nilsson, R., Tegner, J., Hamsten, A., & Bjorkegren, J. (2007). Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proceedings of the National Academy of Sciences of the United States of America, 104(34), 13768–13773. doi:10.1073/pnas.0706027104.
Teupser, D., Weber, O., Rao, T. N., Sass, K., Thiery, J., & Fehling, H. J. (2011). No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. The Journal of Biological Chemistry, 286(8), 6272–6279. doi:10.1074/jbc.M110.161414.
Mause, S. F., & Weber, C. (2010). Microparticles: protagonists of a novel communication network for intercellular information exchange. Circulation Research, 107(9), 1047–1057. doi:10.1161/CIRCRESAHA.110.226456.
Suades, R., Padro, T., Vilahur, G., & Badimon, L. (2012). Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thrombosis and Haemostasis, 108(6), 1208–1219. doi:10.1160/TH12-07-0486.
Leroyer, A. S., Tedgui, A., & Boulanger, C. M. (2008). Role of microparticles in atherothrombosis. Journal of Internal Medicine, 263(5), 528–537. doi:10.1111/j.1365-2796.2008.01957.x.
Sternik, L., Samee, S., Schaff, H. V., Zehr, K. J., Lerman, L. O., Holmes, D. R., et al. (2002). C-reactive protein relaxes human vessels in vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 22(11), 1865–1868.
Khreiss, T., Jozsef, L., Potempa, L. A., & Filep, J. G. (2004). Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation, 110(17), 2713–2720. doi:10.1161/01.CIR.0000146846.00816.DD.
Molins, B., Pena, E., Vilahur, G., Mendieta, C., Slevin, M., & Badimon, L. (2008). C-reactive protein isoforms differ in their effects on thrombus growth. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(12), 2239–2246. doi:10.1161/ATVBAHA.108.174359.
Khreiss, T., Jozsef, L., Potempa, L. A., & Filep, J. G. (2004). Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation, 109(16), 2016–2022. doi:10.1161/01.CIR.0000125527.41598.68.
Khreiss, T., Jozsef, L., Potempa, L. A., & Filep, J. G. (2005). Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circulation Research, 97(7), 690–697. doi:10.1161/01.RES.0000183881.11739.CB.
Zouki, C., Haas, B., Chan, J. S., Potempa, L. A., & Filep, J. G. (2001). Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion. Journal of Immunology, 167(9), 5355–5361.
Mok, C. C., Ying, S. K., Ma, K. M., & Wong, C. K. (2013). Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial. Lupus, 22(14), 1470–1478. doi:10.1177/0961203313507987.
Kiefer, C. R., Stock, R. E., Flanagan, S. S., Darling, C. E., Smith, C. S., & Snyder, L. M. (2012). Early verification of myocardial ischemia with a novel biomarker of acute tissue damage: C-reactive protein fractional forms. Clinica Chimica Acta: International Journal of Clinical Chemistry, 413(19–20), 1536–1541. doi:10.1016/j.cca.2012.06.023.
Thiele, J. R., Habersberger, J., Braig, D., Schmidt, Y., Goerendt, K., Maurer, V., et al. (2014). Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy. Circulation, 130(1), 35–50. doi:10.1161/CIRCULATIONAHA.113.007124.
Golomb, B. A., Dang, T. T., & Criqui, M. H. (2006). Peripheral arterial disease: morbidity and mortality implications. Circulation, 114(7), 688–699. doi:10.1161/CIRCULATIONAHA.105.593442.
Kresl, J. J., Potempa, L. A., & Anderson, B. E. (1998). Conversion of native oligomeric to a modified monomeric form of human C-reactive protein. The International Journal of Biochemistry & Cell Biology, 30(12), 1415–1426.
Ying, S. C., Gewurz, H., Kinoshita, C. M., Potempa, L. A., & Siegel, J. N. (1989). Identification and partial characterization of multiple native and neoantigenic epitopes of human C-reactive protein by using monoclonal antibodies. Journal of Immunology, 143(1), 221–228.
Potempa, L. A., Siegel, J. N., Fiedel, B. A., Potempa, R. T., & Gewurz, H. (1987). Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit. Molecular Immunology, 24(5), 531–541.
Taylor, K. E., & van den Berg, C. W. (2007). Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein. Immunology, 120(3), 404–411. doi:10.1111/j.1365-2567.2006.02516.x.
Headland, S. E., Jones, H. R., D’Sa, A. S., Perretti, M., & Norling, L. V. (2014). Cutting-edge analysis of extracellular microparticles using ImageStream(X) imaging flow cytometry. Scientific Reports, 4, 5237. doi:10.1038/srep05237.
Trial, J., Cieslik, K. A., Haudek, S. B., Duerrschmid, C., & Entman, M. L. (2013). Th1/M1 conversion to th2/m2 responses in models of inflammation lacking cell death stimulates maturation of monocyte precursors to fibroblasts. Frontiers in Immunology, 4, 287. doi:10.3389/fimmu.2013.00287.
Yousuf, O., Mohanty, B. D., Martin, S. S., Joshi, P. H., Blaha, M. J., Nasir, K., et al. (2013). High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? Journal of the American College of Cardiology, 62(5), 397–408. doi:10.1016/j.jacc.2013.05.016.
Suades, R., Padro, T., Alonso, R., Mata, P., & Badimon, L. (2013). Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells. Thrombosis and Haemostasis, 110(2), 366–377. doi:10.1160/TH13-03-0238.
Wang, Y., Tao, J., Yang, Z., Tu, C., Xu, M. G., Wang, J. M., et al. (2005). Tumor necrosis factor-alpha induces release of endothelial microparticles from human endothelial cells. Zhonghua xin xue guan bing za zhi [Chinese Journal of Cardiovascular Diseases], 33(12), 1137–1140.
Devaraj, S., Kumaresan, P. R., & Jialal, I. (2011). C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clinical Chemistry, 57(12), 1757–1761. doi:10.1373/clinchem.2011.169839.
Dasgupta, S. K., Abdel-Monem, H., Niravath, P., Le, A., Bellera, R. V., Langlois, K., et al. (2009). Lactadherin and clearance of platelet-derived microvesicles. Blood, 113(6), 1332–1339. doi:10.1182/blood-2008-07-167148.
Mobarrez, F., He, S., Broijersen, A., Wiklund, B., Antovic, A., Antovic, J., et al. (2011). Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thrombosis and Haemostasis, 106(2), 344–352. doi:10.1160/TH10-12-0810.
Devaraj, S., Du Clos, T. W., & Jialal, I. (2005). Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(7), 1359–1363. doi:10.1161/01.ATV.0000168573.10844.ae.
Ji, S. R., Ma, L., Bai, C. J., Shi, J. M., Li, H. Y., Potempa, L. A., et al. (2009). Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 23(6), 1806–1816. doi:10.1096/fj.08-116962.
Li, H. Y., Wang, J., Wu, Y. X., Zhang, L., Liu, Z. P., Filep, J. G., et al. (2014). Topological localization of monomeric C-reactive protein determines proinflammatory endothelial cell responses. The Journal of Biological Chemistry, 289(20), 14283–14290. doi:10.1074/jbc.M114.555318.
Stoger, J. L., Gijbels, M. J., van der Velden, S., Manca, M., van der Loos, C. M., Biessen, E. A., et al. (2012). Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis, 225(2), 461–468. doi:10.1016/j.atherosclerosis.2012.09.013.
Oliveira, R. T., Silva, R. M., Teo, F. H., Mineiro, M. F., Ferreira, M. C., Altemani, A., et al. (2013). Detection of TCD4+ subsets in human carotid atheroma. Cytokine, 62(1), 131–140. doi:10.1016/j.cyto.2013.02.004.
Zhang, L., Liu, S. H., Wright, T. T., Shen, Z. Y., Li, H. Y., Zhu, W., et al. (2015). C-reactive protein directly suppresses Th1 cell differentiation and alleviates experimental autoimmune encephalomyelitis. Journal of Immunology, 194(11), 5243–5252. doi:10.4049/jimmunol.1402909.
Yanagita, T., Yamamoto, K., Ishida, S., Sonda, K., Morito, F., Saku, K., et al. (1994). Effects of simvastatin, a cholesterol synthesis inhibitor, on phosphatidylcholine synthesis in HepG2 cells. Clinical Therapeutics, 16(2), 200–208.
Prasad, K. (2006). C-reactive protein (CRP)-lowering agents. Cardiovascular Drug Reviews, 24(1), 33–50. doi:10.1111/j.1527-3466.2006.00033.x.
Albert, M. A., Danielson, E., Rifai, N., & Ridker, P. M. (2001). Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA : The Journal of the American Medical Association, 286(1), 64–70.
Wang, C. Y., Liu, P. Y., & Liao, J. K. (2008). Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends in Molecular Medicine, 14(1), 37–44. doi:10.1016/j.molmed.2007.11.004.
Antonopoulos, A. S., Margaritis, M., Lee, R., Channon, K., & Antoniades, C. (2012). Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Current Pharmaceutical Design, 18(11), 1519–1530.
Acknowledgments
We are grateful for the CRP antibody donation of Dr. Larry Potempa (Roosevelt University, Chicago, Illinois). We would like to thank all subjects who participated in the study, Tenille Epperson and Joe L. Raya for their technical assistance and the MD Anderson Cancer Center Flow Cytometry Core for their assistance with the Amnis cytometer.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Compliance with Ethical Standards
The study was conducted in accordance with the ethical standards of the Helsinki declaration and its later amendments and with the ethical standards and approval of the Institutional Review Board of Baylor College of Medicine. Informed consent was obtained from all individual participants included in the study. No animal studies were carried out by the authors for this article.
Sources of Funding
This work was supported by the National Institutes of Health [T32AI053831-10 to J.R.C., RO1 HL-089792 to M.L.E.], Bethesda, Maryland; the Hankamer Foundation, Houston, Texas; the Vivian L. Smith Foundation, Houston, Texas; and The Medallion Foundation, Houston, Texas.
Conflict of Interest
V.N. and R.C.H. are co-investigators on a provisional patent filed by Roche for use of biomarkers in heart failure prediction. The other authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. V.N. has indicated that he has served on the regional advisory board (once) for Sanofi-Regeneron.
Additional information
Associate Editor Enrique Lara-Pezzi oversaw the review of this article
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
ESM 1
(PDF 725 kb)
Rights and permissions
About this article
Cite this article
Crawford, J.R., Trial, J., Nambi, V. et al. Plasma Levels of Endothelial Microparticles Bearing Monomeric C-reactive Protein are Increased in Peripheral Artery Disease. J. of Cardiovasc. Trans. Res. 9, 184–193 (2016). https://doi.org/10.1007/s12265-016-9678-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12265-016-9678-0